Edwards Lifesciences Corp

Day range

$88.97 – $91.05

Open

$90.11

Prev close

$90.09

Volume

3.1M

Market cap

$51.93B

Shares out

575.8M

P/E

51.67

P/S

7.97

P/B

4.89

P/FCF

36.22

ROE

9.5%

ROA

7.2%

Debt/Equity

0.06

Div yield

0.00%

As of Oct 22, 2026

• Executive leadershipAug 28, 2026

  The Board of Directors of Edwards Lifesciences Corporation has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027. A selection process will begin promptly to identify a successor, which is expected to result in a transition of duties during 2027. Mr. Bobo is also expected to remain as a consultant with the Company through the end of 2027.

• Shareholder meetingsMay 8, 2026

  The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting, which was held on May 7, 2026, are as follows: All the nominees for director listed in Proposal 1 were elected to serve until the Company's next annual meeting of stockholders and until their respective successors are duly elected and qualified.

• Executive leadershipMay 4, 2026

  Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position. Ms. Mistras, age 44, has served as Chief Financial Officer of Viatris, Inc. (NASDAQ: VTRS), a global pharmaceutical and healthcare corporation, since March 1, 2024.

• Deal terminationsJan 12, 2026

  the United States District Court for the District of Columbia has granted the motion from the U.S. Federal Trade Commission for an injunction blocking the Company's proposed acquisition of JenaValve Technology, Inc. As a result, the Company will not acquire JenaValve.

• Executive leadershipOct 30, 2025

  Scott Ullem, the Chief Financial Officer of Edwards Lifesciences Corporation, a Delaware corporation (the "Corporation"), informed the Corporation of his decision to transition from his role by mid-year 2026. On October 30, 2025, the Corporation issued a press release announcing his decision. The Corporation is initiating a selection process to appoint a new Chief Financial Officer.

• AMNAMN Healthcare Services+2.54%
• HSICHenry Schein Inc-1.21%

Days to cover

2.5

Short interest

9.54M

Avg volume

3.88M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• INSP Stock Gains 47.8% in Three Months: What's Driving the Rally?
  positiveZacks Investment Research· Oct 23, 2026
• DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
  neutralZacks Investment Research· Oct 22, 2026
• Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
  positiveZacks Investment Research· Oct 7, 2026
• Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
  positiveZacks Investment Research· Sep 1, 2026
• TRiCares Announces Initiation of TRICURE US IDE Pivotal Study for Topaz Tricuspid Valve Replacement System
  neutralGlobeNewswire Inc.· Jul 9, 2026